Gilead, Parion partner on pulmonary disease

Parion Sciences has signed on Gilead to partner up on pulmonary disease therapies. Gilead will pay $5 million up front and $5 million in exchange for an equity stake in Parion for worldwide commercialization rights to P-680. A successful development program would be worth up to $146 million in milestones for Parion. Just as significantly, the two companies say they will collaborate on new research into similar drugs

- see this release
- read the AP report for more info

Related Articles:
Gilead banking $1.3B for new deals. Report
Gilead notes success of trial for cystic fibrosis. Report
Gilead hesitant to tout drug for AIDS prevention. Report
Gilead shares surge on $2.5B Myogen buyout. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.